Updated on February 15, 2024


Created on August 5, 2019

HemoCue Hb 201 Data Management System

Upcoming Update

The HemoCue Hb 201 DM system allows for simple data management in point-of-care blood testing for Hb and anemia screening.

Developed By
  1. HemoCue
Tested By
  • Center for Biologics Evaluation and Research (CBER)
  • HemoCue
Content Partners


Product Description

The HemoCue Hb 201 DM system is a data management solution for hemoglobin testing and anemia screening. It is a way to manage patient information as it has QC lockout and barcode scanning for patient ID. The HemoCue system can be linked with existing systems using POCT-1A (Point of Care Testing standards).

Target SDGs

SDG 3: Good Health and Well-Being

Market Suggested Retail Price


Target Users (Target Impact Group)

Small and Medium-sized Enterprises, Public Sector Agencies

Distributors / Implementing Organizations

Some Larger Distributors include: Radiometer Medical, HCE (Health Care Equipment) and CliaWaived.com Distributors vary by country, more information can be found on HemoCue's website: Europe, Asia/Pacific, Middle East.

Manufacturing/Building Method

The product is mass-produced by HemoCue, headquartered in Sweden.

Intellectural Property Type


User Provision Model

HemoCue has a number of distributors in their target countries in Asia, Europe, Middle East, and the Americas. Users can purchase the DM system from these distributors.

Distributions to Date Status

The distribution to date is unknown.  


HemoCue Hb 201 microcuvettes

Blood test materials (lancet, disinfectant, gloves)

Detection sensitivity

0 – 25.6 g/dL (0 – 256 g/L, 0 – 15.9 mmol/L)

Indispensable equipment for function (Y/N)


Maintenance or calibration required by user at time of use? (Y/N)


Number of Tests Performed


Power supply type: Continuous, Recharging only (V, time required, battery life), Other

Rechargeable battery and AC adapter

Time required for procedure (minutes)

1 min

Design Specifications

A blood sample is collected in a HemoCue microcuvette which is placed in the device. The user then follows the steps on the screen to run the test. The specification of the operation can be found in this manual.

Product Schematics

Technical Support

There is a user manual for the system. Additional technical support is provided by HemoCue distributors and their technicians based on location.  

Replacement Components

To purchase replacement components the user should contact their local distributor.



Manufacturer Specified Performance Parameters

  • Factory calibrated against the ICSH reference method
  • Results within 60 seconds
  • Results Storage: 4,000 patient/STAT tests, 500 QC tests, 500 analyzer logs, 200 patient IDs
  • Reduced transcription errors
  • Wireless connection capabilities
  • Lab quality accuracy

Vetted Performance Status

This product correctly classified patients’ anemic status in 80% or more of instances. The HemoCue® gravity method was found to be more accurate than the HemoCue® wicking method.


There is a risk of inaccurate results if the storage instructions are not followed.

Complementary Technical Systems

The HemoCue Hb system can be connected with existing systems as it complies with the Point of Care Connectivity standard. The system has bidirectional communication with middleware applications such as RALS, AegisPOC, & Telcor.

Academic Research and References

Sanchis-Gomar, F., Cortell-Ballester, J., Pareja-Galeano, H., Banfi, G. and Lippi, G., 2012, Hemoglobin Point-of-Care Testing, Journal of Laboratory Automation, 18(3), pp. 198–205.

Parker, M., Han, Z., Abu-Haydar, E., Matsiko, E., Iyakaremye, D., Tuyisenge, L., Margaret, A. and Lyambabaje, A., 2018, An Evaluation of Hemoglobin Measurement Tools and their Accuracy and Reliability when Screening for Child Anemia in Rwanda: A Randomized Study, Plos One, 3(1).

Gwetu, T.P. and Chhagan, M.K., 2015, Evaluation of the Diagnostic Accuracy of the HemoCue Device for Detecting Anaemia in Healthy School- Aged Children in KwaZulu-Natal, South Africa, South African Medical Journal, 105(7), p. 596.

Levy, T.S., Méndez-Gómez-Humarán, I., Ruán, M.D.C.M., Tapia, B.M., Hernández, S.V. and Ávila, M.H., 2017, Validation of Masimo Pronto 7 and HemoCue 201 for Hemoglobin Determination in Children From 1 to 5 years of Age, Plos One, 12(2).

Marwick, P.C., Johnson, M., Coetzee, J.F., Levin, A.I., 2016, Abstract PR612: Hemocue® Haemoglobin Concentration Measurements are More Accurate than those of Blood Gas Analysers and Assist in Avoiding Incorrect Transfusion Decisions, Anesthesia & Analgesia, 123, pp. 779–780.

HemoCue, “Operation Manual

HemoCue, “Instructions

HemoCue, “Indications of Use“, DEPARTMENT OF HEALTH & HUMAN SERVICES, 2004.

Class 2 Device Recall HEMOCUE Hb 201 DM ANALYZER“, U.S. Food and Drug Administration

Compliance with regulations

The HemoCue 201 Hb DM system is FDA approved. It complies with the 7-71 CLSI H15-A3 (Replaces H15-A2) standard for Quantitative Determination of Hemoglobin in Blood. The HemoCue 201 Hb DM system and the HemoCue 201 Microcuvettes has a CE - Mark. The HemoCueHb 201 Microcuvettes comply with the IVD Medical Device Direc-tive 98/79/EC and carry the CE mark. This, therefore, means that the product is approved for use in the European community.

Evaluation methods

A premarket evaluation was done by the Center for Biologics Evaluation & Research (CBER). Evaluation methods involved comparing the results of HemoCue blood tests to laboratory results for the same patients.   In another research by Back et al. - Between 119 and 138 samples were analyzed at 4 different hospitals - Correlation for all systems against the reference method was better than 0.99 - Correlations between the new Hb 201+ and ADVIA 120 (Bayer Diagnostics), GEN-S (Beckman Coulter), Sysmex XE 2100, CellDyn 4000 (Abbott), and the HemoCue B-Hemoglobin system showed all r > 0.99. - The Hb 201+ system yields results that agreed well with comparative systems. - The system achieved accuracy and precision similar to the available cell counters.

Other Information

In 2011 the system was recalled for 3 months due to a programming error.

Comments from the Community


  1. E4C.COMMENTS says:

    Jeremy Schonhorn says:

    Hemocue IP

    Lindberg, Stellan, and Johnny Svensson. 2009. Enumeration of white blood cells. USPTO 7521243. US Patent, filed April 11, 2005, and issued April 21, 2009. https://www.google.com/pate….

  2. Stephen_Advisor says:

    Sweden is spelled incorrectly in the “Manufacturing/building method(s)” section. The first sentence in the “User Provision Model” section is not clear and should be rewritten.

    Regarding the “Distribution to date”, even if exact numbers are not known, a rough order of magnitude estimation would add significant value.

Leave a Reply

Explore similar solutions


February 15, 2024

HemoCue WBC DIFF System

Read Solution

Implemented by



May 21, 2024

Vaccine Management Solution using e-voucher

Read Solution


May 13, 2024

SORMAS (Surveillance Outbreak Response Management & Analysis System)

Read Solution


January 19, 2024

Clean Team Toilet and Clean Team Toilet Waste Management Service

Read Solution

Implemented by

Clean Team Ghana


April 9, 2024

Myanmar Information Management Unit (MIMU)

Read Solution

Implemented by



January 22, 2024

Sanergy Fresh Life Toilet and Sanergy Fresh Life Waste Management Service

Read Solution

Implemented by



January 17, 2024

Sanima Waste Management Service

Read Solution

Implemented by



June 4, 2024

Open Data Kit

Read Solution

Implemented by

University of Washington


June 20, 2024

Premise Data

Read Solution

Implemented by



April 17, 2024

Humanitarian Data Exchange

Read Solution

Implemented by


All Solutions

Contribute to E4C's Library of Breakthrough Sustainable Development Technology Solutions

Suggest A Solution

Get more information about Solutions Library and its features.

Learn More

Have thoughts on how we can improve?

Give Us Feedback

Join a global community of changemakers.

Become A Member